I initially thought the phase 2/3b trial was our best chance to yield (interim) results that could potentially lead to early approval but with the sluggish enrollment, it may very well be the phase 2 mild to moderate that completes first.

Does anyone here have the latest enrollment count for either? With the phase 2, I believe it's just 75 patients, the "treatment window" is 6 weeks but I never heard of any plan for interim results being reviewed. Is there any reason why this is and could this be changed?